SCYX News and Press, SCYNEXIS Inc. From 07/27/21

SCYNEXIS lead drug candidate BREXAFEMME recently got FDA approval for the treatment of Vulvovaginal Candidiasis, commonly known as vaginal yeast infections. BREXAFEMME is the first approved drug in the non-azole class for VVC and also the first approved drug in a novel antifungal clas...

FURI and CARES presentations show ibrexafungerp’s strong clinical response in difficult-to-treat and refractory fungal infections in the hospital setting including Candida auris In vitro data demonstrates ibrexafungerp’s broad activity against 967 clinical Cand...

JERSEY CITY, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Eric Francois, Chief Financial Officer, will presen...

JERSEY CITY, N.J., July 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to four new employees to ...

BREXAFEMME, a one-day, novel, oral treatment for vaginal yeast infection, is the first FDA-approved indication of the ibrexafungerp antifungal development pipeline and the first approved drug from a novel antifungal class in over 20 years Commercial launch update call is sch...

Company presentation will highlight BREXAFEMME ® (ibrexafungerp tablets), the first FDA-approved product in the ibrexafungerp development pipeline, in addition to ongoing programs in the hospital setting JERSEY CITY, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- SCYNE...

Scynexis (SCYX) announces that the FDA has granted Brexafemme (ibrexafungerp tablets), five years of exclusivity extension under the Generating Antibiotic Incentives Now ((GAIN)) Act.This grant will be added to any other applicable exclusivity periods, such as the five years of new chemical e...

BREXAFEMME to receive 5-year exclusivity extension under the GAIN Act for a total of 10 years of regulatory exclusivity BREXAFEMME also protected by composition-of-matter patent until 2035 Commercial launch update call is scheduled for Tuesday, June 29 th @ 1...

Crestone Joins Antimicrobials Working Group PR Newswire WASHINGTON , June 8, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug r...

Gainers: BriaCell Therapeutics (BCTX) +91%.AMC Entertainment (AMC) +76%.Constellation Pharmaceuticals (CNST) +67%.Bed Bath & Beyond (BBBY) +45%.PetMed Express (PETS) +34%.Urban One (UONE) +31%.Vision Marine Technologies (VMAR) +28%.U.S. Well Services (USWS) +24%.Skillz (SKLZ)&#x...